Sylvia Adams, MD

  • Specialties: Solid Tumors, Oncology
  • Languages: English, German
  • Phone: 212-731-5795

About Me

Conditions and Treatments

breast cancer, immunotherapy, cancer chemotherapy, cancer hormonal therapy, cancer screening, prevention of cancer

Credentials

Positions

  • Associate Professor, Department of Medicine

Board Certifications

    2013
  • American Board of Internal Medicine (Medical Oncology)

Education and Training

  • 2003
  • Fellowship, NYU Medical Center, Hematology Oncology
  • 2000
  • Residency, Winthrop University Hospital, Medicine
  • 1995
  • MD from Friedrich Schiller University

Departments

Locations and Appointments

64 Insurance Plans Accepted
  • Aetna HMO
  • Aetna Indemnity
  • Aetna Medicare
  • Aetna POS
  • Aetna PPO/EPO
  • Affinity
  • Affinity Exchange- Essential
  • Cigna EPO/POS
  • Cigna PPO
  • ElderPlan
  • Empire Blue Cross Blue Shield EPO
  • Empire Blue Cross Blue Shield HMO
  • Empire Blue Cross Blue Shield Healthy NY
  • Empire Blue Cross Blue Shield Indemnity
  • Empire Blue Cross Blue Shield MediBlue
  • Empire Blue Cross Blue Shield POS
  • Empire Blue Cross Blue Shield PPO
  • Empire Blue Cross Blue Shield Pathways, Enhanced
  • Fidelis Child Health
  • Fidelis Family Health
  • Fidelis Medicaid
  • GHI CBP
  • HIP Access I
  • HIP Access II
  • HIP Child Health
  • HIP EPO/PPO
  • HIP Family Health
  • HIP HMO
  • HIP Medicaid
  • HIP Medicare
  • HIP POS
  • HealthPlus Child Health (Amerigroup)
  • HealthPlus Family Health (Amerigroup)
  • HealthPlus Medicaid (Amerigroup)
  • HealthRepublic
  • HealthSmart (WTC)
  • Hotel Trades
  • Humana Medicare
  • Local 1199 PPO
  • MagnaCare PPO
  • Medicare
  • MetroPlus Child Health
  • MetroPlus Exchange Plans
  • MetroPlus Family Health
  • MetroPlus Medicaid
  • MultiPlan/PHCS PPO
  • NY Medicaid
  • NYS Empire Plan
  • Oscar
  • Oxford Exchange
  • Oxford Freedom
  • Oxford Liberty
  • Oxford Medicare
  • Tricare
  • UPN Elite
  • United Exchange- Compass
  • UnitedHealthcare Community & State Plan
  • UnitedHealthcare EPO
  • UnitedHealthcare HMO
  • UnitedHealthcare Medicare
  • UnitedHealthcare POS
  • UnitedHealthcare PPO
  • UnitedHealthcare Top Tier
  • Visiting Nurse Service (VNS) Medicare
*Insurance listed above may not be accepted at all office locations. Please confirm prior to each visit. The information presented here may not be complete or may have been changed.

NYU Medical Oncology Associates
160 East 34th Street
New York, NY 10016

Contact

Phone: 212-731-5795

NYU Medical Oncology Associates
550 1st Avenue
New York, NY 10016

Contact

Phone: 212-652-1922

Welcome back!

As a returning patient for this doctor, please schedule an appointment using your MyChart at NYU Langone account.

Learn more about MyChart at NYU Langone.

Publications

  • Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High Risk Melanoma

    Lubong Sabado, Rachel; Pavlick, Anna; Gnjatic, Sacha; Cruz, Crystal M; Vengco, Isabelita; Hasan, Farah; Spadaccia, Meredith; Darvishian, Farbod; Chiriboga, Luis; Holman, Rose Marie; Escalon, Juliet; Muren, Caroline; Escano, Crystal; Yepes, Ethel; Sharpe, Dunbar; Vasilakos, John P; Rolnitzky, Linda; Goldberg, Judith D; Mandeli, John P; Adams, Sylvia; Jungbluth, Achim A; Pan, Linda; Venhaus, Ralph; Ott, Patrick A; Bhardwaj, Nina 2015 Jan; 1723-1738, Cancer immunology research — id: 1447932, year: 2015, page: 1723, stat: JOURNAL ARTICLE
  • Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199

    Adams, Sylvia; Gray, Robert J; Demaria, Sandra; Goldstein, Lori; Perez, Edith A; Shulman, Lawrence N; Martino, Silvana; Wang, Molin; Jones, Vicky E; Saphner, Thomas J; Wolff, Antonio C; Wood, William C; Davidson, Nancy E; Sledge, George W; Sparano, Joseph A; Badve, Sunil S 2014 Jul; 386-387, Journal of clinical oncology — id: 1089992, year: 2014, page: 386, stat: JOURNAL ARTICLE
  • Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199

    Adams, Sylvia; Gray, Robert J; Demaria, Sandra; Goldstein, Lori; Perez, Edith A; Shulman, Lawrence N; Martino, Silvana; Wang, Molin; Jones, Vicky E; Saphner, Thomas J; Wolff, Antonio C; Wood, William C; Davidson, Nancy E; Sledge, George W; Sparano, Joseph A; Badve, Sunil S 2014 Sep; 2959-2967, Journal of clinical oncology — id: 1411142, year: 2014, page: 2959, stat: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Read All Publications (55)